SCHEMBL680383

SCHEMBL680383

CCCCCCCCCCCCCC(=O)N[N+](C)(C)CCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.53
FAAH O00519 8/20 0.52
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
MAPK1 P28482 1/20 0.48
CES2 O00748 3/20 0.45
CES1 P23141 3/20 0.45
PPARG P37231 4/20 0.43
PPARD Q03181 4/20 0.43
PPARA Q07869 4/20 0.43
TSHR P16473 3/20 0.43
GPR84 Q9NQS5 3/20 0.43
HDAC11 Q96DB2 3/20 0.43
ALDH1A1 P00352 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
SLC22A6 Q4U2R8 1/20 0.43
SLC22A8 Q8TCC7 1/20 0.43
TLR2 O60603 1/20 0.43
ESR1 P03372 1/20 0.43
FABP4 P15090 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9509447 1.00 HSP90AA1 (0.53) HSP90AA1FAAHMEN1KMT2AMAPK1
SCHEMBL1482878 1.00 HSP90AA1 (0.53) HSP90AA1FAAHMEN1KMT2AMAPK1
SCHEMBL15994305 1.00 HSP90AA1 (0.53) HSP90AA1FAAHMEN1KMT2AMAPK1
SCHEMBL74724 1.00 HSP90AA1 (0.53) HSP90AA1FAAHMEN1KMT2AMAPK1
SCHEMBL9409008 1.00 HSP90AA1 (0.53) HSP90AA1FAAHMEN1KMT2AMAPK1
SCHEMBL90355 1.00 HSP90AA1 (0.53) HSP90AA1FAAHMEN1KMT2AMAPK1
SCHEMBL74417 1.00 HSP90AA1 (0.53) HSP90AA1FAAHMEN1KMT2AMAPK1
SCHEMBL23352 1.00 HSP90AA1 (0.53) HSP90AA1FAAHMEN1KMT2AMAPK1
SCHEMBL10420923 1.00 HSP90AA1 (0.53) HSP90AA1FAAHMEN1KMT2AMAPK1
Hydrochloric Acid SCHEMBL4943874 0.98 HSP90AA1 (0.52) HSP90AA1FAAHMEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4716693-A2 PHARMACEUTICAL COMPOSITIONS FOR ANTIBODIES AND MAKING AND USING THE SAME INVETX, INC. (US) 2026-04-01 EP claimed
WO-2024243322-A9 PHARMACEUTICAL COMPOSITIONS FOR ANTIBODIES AND MAKING AND USING THE SAME INVETX, INC. (US) 2025-03-27 WO claimed
WO-2024243322-A2 PHARMACEUTICAL COMPOSITIONS FOR ANTIBODIES AND MAKING AND USING THE SAME INVETX, INC. (US) 2024-11-28 WO claimed
US-20240392009-A1 PHARMACEUTICAL COMPOSITIONS FOR ANTIBODIES AND MAKING AND USING THE SAME INVETX INC (US) 2024-11-28 US claimed
CN-118215507-A Lyophilized ENPP1 polypeptide formulations and uses thereof 依诺兹梅制药公司 2024-06-18 CN claimed
EP-4142681-A1 ANHYDROUS COSMETIC COMPOSITION COMPRISING POLYOLS, MONOALCOHOLS, FATTY AMINES AND AT LEAST 0.1% OF CARBOXYLIC ACIDS L'OREAL (FR) 2023-03-08 EP claimed
CN-115721732-A Pharmaceutical composition and preparation of antibody-conjugated drug, preparation method and application thereof 上海复旦张江生物医药股份有限公司 2023-03-03 CN claimed
CN-114761047-A High hyaluronate multipurpose disinfectant for ophthalmic applications CIS制药股份公司 2022-07-15 CN claimed
WO-2021219547-A1 ANHYDROUS COSMETIC COMPOSITION COMPRISING POLYOLS, MONOALCOHOLS, FATTY AMINES AND AT LEAST 0.1% OF CARBOXYLIC ACIDS L'OREAL (FR) 2021-11-04 WO claimed
CN-113056199-A Trisubstituted biguanide compounds and uses thereof 陈煌兴 2021-06-29 CN claimed
EP-1576081-B1 USE OF MULTIFUNCTIONAL SURFACE ACTIVE AGENTS TO CLEAN CONTACT LENSES ALCON INC (CH) 2007-07-25 EP claimed
US-20070059332-A1 MULTI PURPOSE CONTACT LENS CARE COMPOSITIONS INCLUDING PROPYLENE GLYCOL OR GLYCERIN ADVANCED MEDICAL OPTICS, INC. (US) 2007-03-15 US claimed
US-20060188455-A1 Siloxanes containing guanidino groups and use thereof for cosmetic formulations EVONIK DEGUSSA GMBH (DE) 2006-08-24 US claimed
US-20060188456-A1 UV-light-absorbing quaternary polysiloxanes EVONIK DEGUSSA GMBH (DE) 2006-08-24 US claimed
WO-2006081927-A1 SILOXANES COMPRISING GUANIDINO GROUPS AND USE THEREOF FOR COSMETIC FORMULATIONS GOLDSCHMIDT GMBH (DE) 2006-08-10 WO claimed
EP-1688453-A1 UV light absorbing quaternary polysiloxanes Goldschmidt GmbH (DE) 2006-08-09 EP claimed
EP-1190718-B1 Ophthalmic compositions comprising amino alcohols ALCON LAB INC (US) 2006-05-24 EP claimed
EP-1190718-A2 Ophthalmic compositions comprising amino alcohols ALCON LABORATORIES, INC. (US) 2002-03-27 EP claimed
EP-0562639-B1 Shampoo compositions and suspending agent therefor CURTIS HELENE IND INC (US) 1997-10-29 EP claimed
EP-0562637-B1 Opacifier for water-based compositions CURTIS HELENE IND INC (US) 1997-05-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060188455-A1 Siloxanes containing guanidino groups and use thereof for cosmetic formulations UNG, GMPS, GLA HSP90AA1 1740/4885FAAH 2519/4885MEN1 3802/4885
US-20060188456-A1 UV-light-absorbing quaternary polysiloxanes UBE2I, UFL1, ERCC4 HSP90AA1 985/4885FAAH 2660/4885MEN1 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.